BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.06B |
| 2 |
Tesla
TSLA
|
+$468M |
| 3 |
AbbVie
ABBV
|
+$312M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$266M |
| 5 |
Abbott
ABT
|
+$254M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$609M |
| 2 |
Apple
AAPL
|
+$577M |
| 3 |
Visa
V
|
+$476M |
| 4 |
iShares MSCI ACWI ETF
ACWI
|
+$434M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$239M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.37% |
| 2 | Financials | 8.23% |
| 3 | Consumer Discretionary | 6.83% |
| 4 | Healthcare | 6.12% |
| 5 | Communication Services | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
3301
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $29.4K | ﹤0.01% |
1,342
-7,771
| -85% | -$173K |
|
3302
IDEAYA Biosciences
IDYA
$3.56B
| $29.4K | ﹤0.01% |
1,399
-5,286
| -79% | -$109K |
|
3303
Universal Technical Institute
UTI
$1.41B
| $29.2K | ﹤0.01% |
4,505
-2,779
| -38% | -$16.4K |
|
|
SPNS
3304
DELISTED
Sapiens International
SPNS
| $29.1K | ﹤0.01% |
1,109
-2,433
| -69% | -$71.9K |
|
3305
Transmedics
TMDX
$3.02B
| $29.1K | ﹤0.01% |
877
-2,337
| -73% | -$64.8K |
|
3306
Aclaris Therapeutics
ACRS
$860M
| $29.1K | ﹤0.01% |
+1,656
| New | +$37.6K |
|
|
NVO
3307
Novo Nordisk
NVO
$203B
| $29.1K | ﹤0.01% |
694
-404
| -37% | -$15.7K |
|
|
SP
3308
DELISTED
SP Plus Corporation
SP
| $29K | ﹤0.01% |
947
-10,036
| -91% | -$329K |
|
|
PSTL
3309
Postal Realty Trust
PSTL
$702M
| $28.9K | ﹤0.01% |
+1,586
| New | +$30.9K |
|
3310
Red River Bancshares
RRBI
$674M
| $28.9K | ﹤0.01% |
572
-1,749
| -75% | -$95K |
|
3311
Ceco Environmental
CECO
$4.44B
| $28.8K | ﹤0.01% |
4,026
-10,582
| -72% | -$81.9K |
|
3312
Establishment Labs
ESTA
$2.25B
| $28.8K | ﹤0.01% |
+330
| New | +$24.6K |
|
|
EPZM
3313
DELISTED
Epizyme, Inc
EPZM
| $28.5K | ﹤0.01% |
3,428
-22,315
| -87% | -$188K |
|
|
ATRS
3314
DELISTED
Antares Pharma, Inc.
ATRS
| $28.2K | ﹤0.01% |
6,471
-15,212
| -70% | -$62K |
|
3315
Rigel Pharmaceuticals
RIGL
$782M
| $28.1K | ﹤0.01% |
649
-3,298
| -84% | -$125K |
|
|
PFBI
3316
DELISTED
Premier Financial Bancorp
PFBI
| $27.8K | ﹤0.01% |
1,652
-4,388
| -73% | -$81.3K |
|
3317
Willis Lease Finance
WLFC
$1.21B
| $27.8K | ﹤0.01% |
1,947
-3,117
| -62% | -$45.5K |
|
3318
Axogen
AXGN
$2.67B
| $27.8K | ﹤0.01% |
1,285
-3,447
| -73% | -$69.7K |
|
3319
Crinetics Pharmaceuticals
CRNX
$8.96B
| $27.7K | ﹤0.01% |
1,472
-2,169
| -60% | -$38.1K |
|
3320
Verastem
VSTM
$629M
| $27.5K | ﹤0.01% |
563
-3,906
| -87% | -$163K |
|
3321
First Bank
FRBA
$469M
| $27.4K | ﹤0.01% |
2,021
-5,630
| -74% | -$73K |
|
3322
Capital Bancorp
CBNK
$617M
| $27.3K | ﹤0.01% |
1,336
-2,750
| -67% | -$58.7K |
|
|
LGTY
3323
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $27.2K | ﹤0.01% |
1,239
-3,043
| -71% | -$64.1K |
|
|
BCEL
3324
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $27.1K | ﹤0.01% |
3,186
-685
| -18% | -$7.02K |
|
3325
Fidelity D&D Bancorp
FDBC
$322M
| $27.1K | ﹤0.01% |
501
-1,346
| -73% | -$75.2K |
|
Similar funds
BNP Paribas Financial Markets's Q2 2021 Portfolio in Review
As of Q2 2021, BNP Paribas Financial Markets held 4,172 positions worth $75.6B, up 11% from $68.3B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
BNP Paribas Financial Markets's Q2 2021 filing shows 175 new, 1,539 increased, 1,937 reduced and 124 closed positions. Its largest new stake was FlexShares Global Upstream Natural Resources Index Fund: 708,078 shares worth $27.1M. The largest sale was Invesco QQQ Trust, an estimated $609M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 13% a quarter earlier, followed by Financials and Consumer Discretionary.
- BNP Paribas Financial Markets's largest Q2 2021 buy was FlexShares Global Upstream Natural Resources Index Fund: 708,078 shares worth $27.1M.
- BNP Paribas Financial Markets added most to State Street SPDR S&P 500 ETF Trust in Q2 2021, an estimated $1.06B increase.
- BNP Paribas Financial Markets's biggest Q2 2021 reduction was Invesco QQQ Trust, cutting an estimated $609M.
- BNP Paribas Financial Markets fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $123M.
- BNP Paribas Financial Markets's ten largest holdings make up 13% of its $75.6B portfolio in Q2 2021.
- BNP Paribas Financial Markets opened 175 new positions and closed 124 in Q2 2021.
- BNP Paribas Financial Markets's portfolio value rose 11% quarter-over-quarter to $75.6B.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2021, filed 10 Aug 2021.